Progression pattern and adverse events with bevacizumab in glioblastoma

BACKGROUND: The use of bevacizumab in the management of glioblastoma multiforme (gbm) remains controversial. In Canada, bevacizumab is approved for the treatment of recurrent gbm. We describe a pattern of progression across treatment lines in gbm. METHODS: During 2008–2014, 64 patients diagnosed wit...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Curr Oncol
Prif Awduron: Mamo, A., Baig, A., Azam, M., Rho, Y.S., Sahebjam, S., Muanza, T., Owen, S., Petrecca, K., Guiot, M.C., Al-Shami, J., Sharma, R., Kavan, P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Multimed Inc. 2016
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5081019/
https://ncbi.nlm.nih.gov/pubmed/27803607
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.23.3108
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg